Hence, CSF Aβ42, plasma-based two fractions of β amyloid peptide ratio (Aβ42/40), and phosphorylated tau (p-tau) are considered promising prospective biomarkers for AD diagnosis and progression (6, 7). The gene discussed is MAPT; the disease is Alzheimer disease.